Guillén-Ortega F, Pérez-Vargas A, Estrada-Suárez A, Moleres-Villegas J, Ricárdez-Esquinca J, Monteón Padilla V, Reyes PA

Language: Spanish
References: 25
Page: 49-54
PDF size: 66.56 Kb.

ABSTRACT

Chagas disease is caused by the flagellate protozoan T. cruzi. Seroepidemiological surveys in Chiapas, Mexico have shown seropositive individuals, therefore, we searched for people affected by the chronic form of Chagas disease which involves the heart, causing a chronic, progressive and fatal disease called Chronic Chagasic Cardiopathy (CCC). Material and methods: To establish the frequency of CCC we studied 28 patients seen at the Hospital General Regional “Dr. Rafael Pascacio Gamboa” during October 2002 through October 2003 in Tuxtla Gutierrez, Chiapas, the State capital city, with diagnosis of dilated cardiomyopathy (DC), a serological survey for antibodies against T. cruzi was done. This hospital cares for people from all parts of Chiapas, Mexico. Clinical diagnosis of DC was established there and blind serological studies were performed in Mexico City. Results: Fifteen out of 28 DC patients (54%) had anti T. cruzi antibodies. All of them came from poor rural villages and they had heart failure and/or arrhythmia or heart blockade on EKG. Conclusions: This observation suggest that in Chiapas were Chagas disease is endemic, there are CCC patients. Any case with a clinical diagnosis of DC should be tested for antibodies against T. cruzi. The low socioeconomic status, culture and environment in this Mexican State favour the presence and transmission of this parasitic disease.

REFERENCES

1. Dumointeil E: Update on Chagas’ disease in México. Salud Publica Mex 1999; 41: 322-7.

2. Guzmán BC: Epidemiology of Chagas disease in México. Trend Parasitol 2001; 17: 372-6.

3. Organización Mundial de la Salud. World Health Organization (WHO): Chagas’ disease. Frequency and geographical distribution. Weeky epidemiological report. 1990.

4. Velasco O, Valdespino J, Tapia R, Salvatierra E, Guzmán C: Seroepidemiología de la enfermedad de Chagas en México. Sal Publ México 1992; 34: 186-196.

5. Organización Mundial de la Salud. World Health Organization (WHO): 1996 Report of Chagas’ disease. Report of a WHO Expert Committee. Series 811. Geneva.

6. Guzmán C, García L, Florián J, Guerrero M, Torres C, Ramírez M, et al: Riesgo de transmisión de Trypanosoma cruzi por transfusión de sangre en México. Panamerican Journal Public Health 1998; 4: 94-99.

7. Monteón V, Hernández N, Guzmán C, Rosales J, Reyes P: American Trypanosomosis (Chagas’ Disease) and blood banking in México City: seroprevalence and its potential transfusional transmission risk. Arch Med Res 1999; 30: 393-398.

8. Goldsmith R, Ortega M, Zarate L, Beltrán F: Seroepidemiologic surveys for Chagas´disease in Chiapas, México. Archivos Investigación Médica México 1983; 14: 43-50.

9. Brandenburg RO, Chazov E, Cherian G, Martín V, Orinius E, Goodwin JF, et al: Report of the WHO/ISFC Task Force on definition and classification of cardiomyopathies. Circulation 1981; 64: 437A-438A.

10. Monteón V, Sosa T, Reyes PA: Serological test for American Trypanosomiasis: A comparative study. Rev Latinoamer Microbiol 1989; 31: 35-38.

11. Monteón V, Ramos A, Reyes PA: Reactividad de sueros de pacientes chagásicos crónicos con extracto de aislamientos mexicanos de Trypanosoma cruzi. Revista Biología Tropical (Costa Rica) 1993; 41: 361-865.

12. Monteón V, Guzmán-Bracho C, Florián-Verdugo J, Ramos-Echavarría A, Reyes PA: Diagnóstico serológico de la enfermedad de Chagas: autosuficiencia y concordancia interlaboratorios. Salud Publ Mex 1995; 37: 232-235.

13. Wynne J, Braunwald E: The cardiomyopathies and Myocarditides. En: Braunwald E, Zipes DP, Libby P, eds: Heart disease: A Textbook of Cardiovascular Medicine. Philadelphia: Saunders; 2001: 1751-1760.

14. Rodas A, Toro S, Ramos A, Monteón V, Pérez P: La incidencia de anticuerpos anti-Trypanosoma cruzi en pacientes con miocardiopatía dilatada en el Instituto Nacional de Cardiología “Ignacio Chávez”. Arch Inst Cardiol Mex 1992; 62: 541-545.

15. Moreno L, Sánchez P, Muñoz J, Monteón V, Reyes P: Cardiopatía chagásica en Tehuantepec. Informe preliminar. Arch Cardiol Mex 2001; 71: 43-49.

16. Cordero L, Zárate R, Ramos M, Cordero J: Miocardiopatía Dilatada Chagásica en el Estado de Chiapas, México. Rev Mex Cardiol 2002; 13(4): 153-157.

17. Monteón VM, Negrete C, Reyes PA: Chronic Chagasic Cardiopathy with Parasitemic state. (Preliminary report) Arch Med Res 1996; 27: 335-7.

18. Zárate LG, Zárate R: A checklist of the Traitominae (Hemiptera: Redivideae) of México. Int J Entomol 1985; 27: 102-27.

19. Ibáñez-Bernal S, Paz-Rodríguez R: Los complejos de especies de Triatoma en México y Centroamérica. En: Proceedings of the Second International Workshop on Population Genetics And Control of Triatominae. Tegucigalpa, Honduras. INDRE. México D.F: 1999: 86-0.

20. Vidal-Acosta V, Ibáñez-Bernal S, Martínez-Campos C: Infección natural de chinches Triatominae con Trypanosoma cruzi asociadas a la vivienda humana en México. Salud Publica Mex 2000; 42: 496-03.

21. Mazariego AMA, Ramírez SJE, Alejandre AR, Nogueda TB: Activity and residual effect of two formulations of lambda-cyhalothrin sprayed on palm tree leaves to Rhodnius prolixus. Mem Inst Oswaldo Cruz 2002; 97: 353-7.

22. Mazariego-Arana M, Monteón V, Ballinas-Verdugo, Hernández-Becerril, Alejandre-Aguilar, Reyes P: Seroprevalence of human Trypanosoma cruzi infection in different geographic zones of Chiapas, México. Rev Soc Bras Med Trop 2001; 34(5): 453-458.

23. Cárdenas J, Mazariego M, Utrilla F, Monteón V, Altuzar M: Anticuerpos anti-Trypanosoma cruzi en pacientes con miocardiopatía dilatada. Rev Med IMSS. 2003; 41(2): 111-114.

24. Vallejo M, Reyes P: Tripanosomosis Americana ¿Un problema sociomédico en México? Arch Inst Cardiol Mex 1996; 66: 95-97.

25. Vallejo M, Montenegro P, Reyes P: ¿Cuánto cuesta la atención de la cardiopatía chagásica crónica? Costos directos del Hospital de Cardiología. Arch Cardiol Mex 2002; 72: 129-137.